teprotumumab
General
Pronunciation:
tep-roe-toom-ue-mab
![](.//images/locked-audio.png)
Trade Name(s)
- Tepezza
Ther. Class.
none assigned
Pharm. Class.
insulin like growth factor1 receptor inhibitors
monoclonal antibodies
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., et al. "Teprotumumab." Davis's Drug Guide, 18th ed., F.A. Davis Company, 2023. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110910/all/teprotumumab.
Vallerand AHA, Sanoski CAC, Quiring CC. Teprotumumab. Davis's Drug Guide. F.A. Davis Company; 2023. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110910/all/teprotumumab. Accessed September 7, 2024.
Vallerand, A. H., Sanoski, C. A., & Quiring, C. (2023). Teprotumumab. In Davis's Drug Guide (18th ed.). F.A. Davis Company. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110910/all/teprotumumab
Vallerand AHA, Sanoski CAC, Quiring CC. Teprotumumab [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2023. [cited 2024 September 07]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110910/all/teprotumumab.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - teprotumumab
ID - 110910
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
AU - Quiring,Courtney,
BT - Davis's Drug Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110910/all/teprotumumab
PB - F.A. Davis Company
ET - 18
DB - Pediatrics Central
DP - Unbound Medicine
ER -